GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncternal Therapeutics Inc (NAS:ONCT) » Definitions » PB Ratio

Oncternal Therapeutics (Oncternal Therapeutics) PB Ratio : 0.81 (As of Apr. 27, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Oncternal Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-27), Oncternal Therapeutics's share price is $8.29. Oncternal Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was $10.19. Hence, Oncternal Therapeutics's PB Ratio of today is 0.81.

The historical rank and industry rank for Oncternal Therapeutics's PB Ratio or its related term are showing as below:

ONCT' s PB Ratio Range Over the Past 10 Years
Min: 0.01   Med: 0.48   Max: 7.09
Current: 0.81

During the past 13 years, Oncternal Therapeutics's highest PB Ratio was 7.09. The lowest was 0.01. And the median was 0.48.

ONCT's PB Ratio is ranked better than
84.26% of 1309 companies
in the Biotechnology industry
Industry Median: 2.38 vs ONCT: 0.81

During the past 12 months, Oncternal Therapeutics's average Book Value Per Share Growth Rate was -52.00% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -39.60% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -31.80% per year. During the past 10 years, the average Book Value Per Share Growth Rate was -22.10% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Oncternal Therapeutics was 101.60% per year. The lowest was -74.10% per year. And the median was -27.50% per year.

Back to Basics: PB Ratio


Oncternal Therapeutics PB Ratio Historical Data

The historical data trend for Oncternal Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncternal Therapeutics PB Ratio Chart

Oncternal Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.25 2.12 1.27 0.94 1.05

Oncternal Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.94 0.88 0.45 0.48 1.05

Competitive Comparison of Oncternal Therapeutics's PB Ratio

For the Biotechnology subindustry, Oncternal Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncternal Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncternal Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Oncternal Therapeutics's PB Ratio falls into.



Oncternal Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Oncternal Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=8.29/10.194
=0.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Oncternal Therapeutics  (NAS:ONCT) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Oncternal Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Oncternal Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncternal Therapeutics (Oncternal Therapeutics) Business Description

Traded in Other Exchanges
Address
12230 El Camino Real, Suite 230, San Diego, CA, USA, 92130
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that targets ROR1 and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers.
Executives
Gunnar F. Kaufmann officer: Chief Scientific Officer C/O ONCTERNAL THERAPEUTICS, INC., 12230 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Salim Yazji officer: Chief Medical Officer 12230 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
James B Breitmeyer director, officer: President, CEO
Richard G Vincent officer: Chief Financial Officer C/O WOMEN FIRST HEALTH CARE, 5355 MIRA SORRENTO PLACE STE. 700, SAN DIEGO CA 92121-3825
Chase C. Leavitt officer: General Counsel/Secretary 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Jill Desimone director C/O PRAXIS PRECISION MEDICINES, INC., 99 HIGH STREET, 30TH FLOOR, BOSTON MA 02110
Rajesh Krishnan officer: Chief Technology Officer 12230 EL CAMINO, SUITE 300, SAN DIEGO CA 92130
Jinzhu Phd Chen director 12230 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Michael G Carter director C/O CANCER VAX CORP, 2110 RUTHERFORD ROAD, CARLSBAD CA 92008
Daniel L Kisner director 2292 FARADAY AVENUE, CARLSBAD CA 92008
Shanghai Pharmaceuticals Holding Co., Ltd. 10 percent owner C/O ONCTEMAL THERAPEUTICS, INC., 12230 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Shanghai Pharmaceuticals (hk) Investment Ltd 10 percent owner C/O ONCTERNAL THERAPEUTICS, INC., 12230 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Shanghai Pharmaceutical (usa) Inc. 10 percent owner C/O ONCTERNAL THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS ROAD #821, SAN DIEGO CA 92130-2122
Hazel M Aker officer: General Counsel C/O CANCER VAX CORP, 2110 RUTHERFORD ROAD, CARLSBAD CA 92008
Man Cho director C/O ONCTERNAL THERAPEUTICS, INC., SUITE 300, SAN DIEGO CA 92130

Oncternal Therapeutics (Oncternal Therapeutics) Headlines